VIDEO From Medialink: FDA Approves New Treatment Option for Colorectal Cancer Patients
Posted on: Friday, 29 September 2006, 18:00 CDT
According to the American Cancer Society, close to 190,000 new cases of colorectal cancer will be diagnosed in the U.S. this year -- making colorectal cancer the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths in the U.S.
(See video at: http://media.medialink.com/WebNR.aspx?story=32456)
Patients have a new treatment option called Vectibix, the first entirely human anti-EGFr antibody to significantly improve progression-free survival as a monotherapy for patients with advanced colorectal cancer. Vectibix is designed to selectively target the epidermal growth factor receptor, which is known to be involved in the development and progression of several cancers. It also offers a convenient once-every-two-week dosing schedule.
Amgen, the developer of Vectibix, is also introducing a new program that will provide financial assistance to cancer patients taking Vectibix. Through this new program, every eligible cancer patient in the U.S. will have access to Vectibix regardless of their ability to pay.
Registered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://media.medialink.com.
Source: Business Wire
Related Articles
- Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
- Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program
- Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Delaware Cancer Patients Among Nation's First to Benefit From Expansion of the American Cancer Society's 'Patient Navigator Program'
- Valeant Pharmaceuticals Announces Availability of Complimentary ``Managing Chemotherapy Side Effects For Dummies'' Cancer Chemotherapy Resource; Special Edition ``For Dummies''(R) Book Now Available for Cancer Chemotherapy Patients and Caregivers
- Phase II Clinical Trial of NeoPharm's LE-SN38 Initiated By NCI CALGB in Patients With Metastatic Colorectal Cancer; First Patients Treated
- Learn the Signs and Symptoms of Colorectal Cancer; March is Colorectal Cancer Awareness Month
- Narrative Review: Screening for Colorectal Cancer in Patients With a First-Degree Relative With Colonic Neoplasia
- Endpoints Met in First Stage of ADVENTRX CoFactor Phase II Metastatic Colorectal Cancer Study; Patient Enrollment Completed in Phase II Study
 |
 |
User Comments (0)
RSS Feeds